Condition
NK Cell
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06835140Phase 1Recruiting
CD123-CD16-NK Cells Immunotherapy for AML
NCT06641648Phase 1Not Yet Recruiting
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
NCT05909098Phase 1Not Yet RecruitingPrimary
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
Showing all 3 trials